KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medtronic (MDT) Cash & Equivalents (2016 - 2026)

Medtronic (MDT) has disclosed Cash & Equivalents for 14 consecutive years, with $1.1 billion as the latest value for Q1 2026.

  • Quarterly Cash & Equivalents fell 7.5% to $1.1 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Jan 2026, down 7.5% year-over-year, with the annual reading at $2.2 billion for FY2025, 72.74% up from the prior year.
  • Cash & Equivalents hit $1.1 billion in Q1 2026 for Medtronic, down from $1.3 billion in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $4.8 billion in Q4 2022 to a low of $1.1 billion in Q1 2026.
  • Historically, Cash & Equivalents has averaged $2.1 billion across 5 years, with a median of $1.4 billion in 2024.
  • Biggest five-year swings in Cash & Equivalents: plummeted 72.85% in 2023 and later soared 72.74% in 2025.
  • Year by year, Cash & Equivalents stood at $4.8 billion in 2022, then tumbled by 72.85% to $1.3 billion in 2023, then grew by 6.33% to $1.4 billion in 2024, then fell by 8.03% to $1.3 billion in 2025, then dropped by 10.53% to $1.1 billion in 2026.
  • Business Quant data shows Cash & Equivalents for MDT at $1.1 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.3 billion in Q3 2025.